Wells Fargo & Company MN raised its holdings in Mylan (NASDAQ:MYL) by 153.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,480,609 shares of the company’s stock after purchasing an additional 896,513 shares during the period. Wells Fargo & Company MN owned 0.28% of Mylan worth $46,447,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of MYL. Bellwether Investment Group LLC lifted its position in Mylan by 0.3% during the second quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock valued at $257,000 after purchasing an additional 23 shares during the last quarter. Suntrust Banks Inc. lifted its position in Mylan by 0.7% during the second quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after purchasing an additional 60 shares during the last quarter. Dai Ichi Life Insurance Company Ltd lifted its position in Mylan by 0.4% during the second quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock valued at $1,009,000 after purchasing an additional 107 shares during the last quarter. Wealthsource Partners LLC lifted its position in Mylan by 1.9% during the second quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock valued at $362,000 after purchasing an additional 177 shares during the last quarter. Finally, Accident Compensation Corp lifted its position in Mylan by 0.3% during the second quarter. Accident Compensation Corp now owns 71,035 shares of the company’s stock valued at $2,758,000 after purchasing an additional 200 shares during the last quarter. 74.90% of the stock is owned by institutional investors.
Mylan (NASDAQ:MYL) traded up $0.80 during trading hours on Tuesday, reaching $43.11. 6,728,000 shares of the company were exchanged, compared to its average volume of 6,320,000. Mylan has a 52 week low of $29.39 and a 52 week high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. The company has a market cap of $22,700.00, a price-to-earnings ratio of 25.97, a P/E/G ratio of 3.15 and a beta of 1.38.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. research analysts predict that Mylan will post 4.56 EPS for the current fiscal year.
Several equities research analysts have issued reports on MYL shares. BidaskClub upgraded shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th. Cantor Fitzgerald reiterated a “hold” rating and set a $34.00 target price on shares of Mylan in a research report on Friday, September 8th. BMO Capital Markets restated a “buy” rating and issued a $45.00 price objective on shares of Mylan in a report on Friday, September 29th. ValuEngine upgraded shares of Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Finally, BTIG Research boosted their price objective on shares of Mylan from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $42.78.
COPYRIGHT VIOLATION WARNING: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.truebluetribune.com/2018/01/03/mylan-n-v-myl-shares-bought-by-wells-fargo-company-mn.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.